Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) Invested Capital (2016 - 2025)

Historic Invested Capital for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $219.8 million.

  • Voyager Therapeutics' Invested Capital fell 3344.89% to $219.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $219.8 million, marking a year-over-year decrease of 3344.89%. This contributed to the annual value of $299.8 million for FY2024, which is 2684.5% up from last year.
  • Voyager Therapeutics' Invested Capital amounted to $219.8 million in Q3 2025, which was down 3344.89% from $243.9 million recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Invested Capital ranged from a high of $340.9 million in Q1 2024 and a low of $59.0 million during Q4 2022
  • Moreover, its 5-year median value for Invested Capital was $199.0 million (2023), whereas its average is $188.2 million.
  • As far as peak fluctuations go, Voyager Therapeutics' Invested Capital tumbled by 4741.09% in 2021, and later skyrocketed by 30040.66% in 2023.
  • Over the past 5 years, Voyager Therapeutics' Invested Capital (Quarter) stood at $95.1 million in 2021, then tumbled by 37.91% to $59.0 million in 2022, then soared by 300.41% to $236.3 million in 2023, then rose by 26.84% to $299.8 million in 2024, then decreased by 26.67% to $219.8 million in 2025.
  • Its Invested Capital stands at $219.8 million for Q3 2025, versus $243.9 million for Q2 2025 and $272.7 million for Q1 2025.